Oral Anticoagulation and the Novel Oral Anticoagulants (NOACs):Where Are We at Midterm?

Academic Content

Program Overview

Faculty Presentations

Introduction Deepak L. Bhatt Elaine Hylek

Video Roundtable

Current Activity

Deepak L. Bhatt, MD, MPH
Interventional Cardiovascular Programs
Brigham & Women’s Hospital
Heart & Vascular Center
Harvard Medical School
Boston, Massachusetts

Overview: Anticoag & NOACs AFib Impact AFib in the USA AFib: Age Prevalence AFib: Age & Gender AFib: Age & Strokes Problems with Warfarin Warfarin INR Values & Stroke CHADS2 & AFib - Index Scores CHADS2 & AFib - Patient Scores The REACH Registry: CVD Events CHA2DS2-VASc Stroke Risk The HAS-BLED Risk Score Markov Decision Analysis Novel Oral Anticoagulants NOACS: Risk Prevention Data NOACS: Secondary Efficacy NOACS: Major Bleeding NOACS: Secondary Safety Potentially Preventable Strokes Anticoagulation in VTE Regulatory Approval Status

Return to:

The American Journal of Medicine

« Prev

Next »
Click Figure to Enlarge

Update Required To play the media you will need to either update your browser to a recent version or update your Flash plugin.

The American Journal of Medicine

Print This Page

Projected Number of Adults with AFib in the United States, 1995–2050

There are many risk factors for AFib, including age, hypertension, and the presence of structural heart disease. All of these may contribute to development of AFib, but probably the major factor driving the big increase in the absolute number of patients with AFib in the United States is the fact that the overall population is aging. With greater age comes greater risk for development of AFib, and as seen in Figure 3,[3] the projected increase in patients with AFib in the United States and worldwide over the next few decades is staggering.

Bhatt D. Am J Med 2014; 00.

References

[3]

Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370-2375.